ANXA5 M2 Haplotyping in IVF Patients and Embryos
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients consenting to participation in the study will receive a saliva collection kit for M2 testing. Genomic Prediction Clinical Laboratory will perform testing and issue a report per routine clinical procedures. Upon completion of issuing a report, the patients' medical records will be obtained from the IVF Center providing care to the patient. Information obtained may include: history of miscarriage, embryo transfer outcomes, preeclampsia, small for gestation age baby, or thrombophilia disorders.
In addition to obtaining records related to history of pregnancy complications, carrier couples will be offered the use of preimplantation genetic testing for M2 carrier status (PGT-M2) in their embryos. Patients electing to perform PGT-M2 will receive PGT-A according to standard clinical practice, along with M2 carrier status.
A total of 500 patients will complete the study and may be recruited from any IVF clinic in the United States. Patients will undergo ovarian hyper-stimulation, oocyte retrieval, fertilization and embryo culture per standard clinical protocol determined by each clinic.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Talia Metzgar, RN
- Phone Number: (973) 529-4223
- Email: Talia@genomicprediction.com
Study Contact Backup
- Name: Bhavini Rana
- Phone Number: (973) 529-4223
- Email: bhavini@genomicprediction.com
Study Locations
-
-
New Jersey
-
North Brunswick, New Jersey, United States, 08902
- Genomic Prediction Clinical Laboratory
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All couples above the age of 18
Exclusion Criteria:
- Any case where biological parental DNA is unavailable.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Infertile patients
Patients attending an IVF center for infertility treatment
|
DNA will be extracted from saliva samples obtained from participants.
Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
M2 Haplotype frequency
Time Frame: 1 month
|
Frequency of carriers of the M2 haplotype attending an IVF center for infertility treatment.
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Genomic Prediction Inc 625
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
NCT01936077CompletedInfertility, Female Infertility, Male Infertility
-
NCT00315029CompletedPregnancy | Male Infertility | Female Infertility
-
NCT02107521TerminatedMale Infertility | Female Infertility
-
NCT03670758UnknownUnexplained Female Infertility
-
NCT04945265Not yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
NCT03323801CompletedMale Infertility, Azoospermia
-
NCT01331395TerminatedPrimary Female Infertility | Secondary Female Infertility
-
NCT01859520CompletedMale Infertility | Unexplained Infertility
-
NCT07611448Enrolling by invitationInfertility (IVF Patients) | Infertility Assisted Reproductive Technology
-
NCT07337265Not yet recruitingMale Infertility | Unexplained Infertility | Sperm DNA Fragmentation
Clinical Trials on M2 Test
-
NCT03757754UnknownEsophageal Cancer
-
NCT04029909UnknownOvarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
-
NCT01379339CompletedSquamous Cell Carcinoma of the Head and Neck
-
NCT03345485CompletedSoft Tissue Sarcoma | Small Cell Lung Cancer | Ovarian Cancer | Endometrial Cancer | Triple-negative Breast Cancer
-
NCT00406757CompletedLeukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic
-
NCT06431243Recruiting
-
NCT07044349Not yet recruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
-
NCT04689282CompletedAutism Spectrum Disorder | Language Delay | Language; Developmental Disorder, Expressive | Language; Developmental Disorder, Receptive | Attention Deficit-Hyperactivity Disorder | Speech Disorders in Children
-
NCT02029430CompletedKaposi's Sarcoma | AIDS | HIV Positive
-
NCT06485219Active, not recruitingCutaneous T-cell Lymphoma (CTCL) | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)